Integra Holdings closes US$3m investment from Guangxi Wuzhou Pharmaceutical Group
To advance existing portfolio companies and create new companies originating from research at the Hebrew University
Integra Holdings, the biotechnology investment company owned by Yissum, the research arm of the Hebrew University of Jerusalem, has received US$3m from Guangxi Wuzhou Pharmaceutical Group, a subsidiary of Chinese investment company Guangxi Wuzhou Zongheng Group. The funds will be used to advance Integra Holdings’ existing portfolio companies and to create new firms based on promising research projects originating from the Hebrew University.
Integra Holdings, founded by Yissum in 2012, has a portfolio of companies operating in a variety of therapeutic areas including oncology, Alzheimer’s disease, infectious diseases, analgesia and inflammation. The products developed by the companies are in various stages of development from pre-clinical to registration. The portfolio currently includes Ayana, Atox Bio, Avraham Pharmaceuticals, Lipomedix, Tiltan Pharma, Lipocure and HIL Applied Medical, in addition to two new companies, which are now being established and developing products.
Investors in Integra Holdings include Invatech Holdings, a group of private US and Israeli investors; Halman-Aldubi Provident and Pension Fund; the Funds of Teaching Personnel and the HUJI Provident Fund. Integra has raised a total of $12m to date.
'We are pleased to have Guangxi Wuzhou Pharmaceutical Group join as an investor which can also assist us in introducing biotech products and technologies based on research performed at the Hebrew University to the Chinese market,' said Yaacov Michlin, CEO of Yissum and Chairman of Integra Holdings' Board of Directors.
'After only two years since its inception, Integra Holdings has obtained an investment at twice its original valuation.'
